As we will discuss later, EGFR-mutant NSCLC is notoriously resistant to immunotherapy, which may be due in part to its uniquely immunosuppressive TME and low tumor mutational burden [33]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.